Eli Lilly & Co. has made significant strides in resolving the shortage of its prominent diabetes and weight-loss drugs, Mounjaro and Zepbound, in the United States. This development has crucial implications for the growing market for compounded medications—often seen as cheaper alternatives to brand-name drugs. As the United States Food and Drug Administration (FDA) confirmed […]
Tag: HealthcareMarket
Back To Top